FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPRO	DVAL
OMB Number:	3235-0287
Estimated average burd	len
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Watts Ryan J.					2. Issuer Name and Ticker or Trading Symbol Denali Therapeutics Inc. [DNLI]								able)	Persoi	10% Ow	ner	
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BOULEVARD, SECOND FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 02/08/2019)	X Officer (give title Other (specify below) President and CEO					
(Street) SOUTH FRANCI	SCO		94080		4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)		C		- ^ -	inad Di		-f D		. 0					
1 Title of 9	Cocurity (Incl		ble I - Non-D	Transact	_	2A. Deem		3.				5. Amour	nt of	6. Own	pershin 7	. Nature of	
Date				Execution Date if any (Month/Day/Yea		, Transaction Code (Ins					es Form ally (D) o Following (I) (Ir d ion(s)		n: Direct or Indirect nstr. 4)	Indirect Beneficial Ownership (Instr. 4)			
					Code V	Amount	(A) oi (D)	Price	Transacti (Instr. 3 a								
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)			
Restricted Stock Units	(1)	02/08/2019		A		11,031		(2)	(2)	Common Stock	11,031	\$0.00	11,031	L	D		
Restricted Stock Units	(1)	02/08/2019		A		35,200		(3)	(3)	Common Stock	35,200	\$0.00	35,200		D		
Stock Option (right to buy)	\$18.13	02/08/2019		A		281,600		(4)	02/07/2029	Common Stock	281,600	\$0.00	281,60	0	D		

Explanation of Responses

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- 2. 50% of the restricted stock units shall vest on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
- 3. 25% of the restricted stock units shall vest on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
- 4. 25% of the shares subject to the option shall vest on February 8, 2020, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

Remarks:

<u>/s/ Tyler Nielsen, by power of attorney</u>

02/11/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.